Nivolumab Cost in India After the Biosimilar Launch

Before January 2026, nivolumab was sold in India only as the Bristol Myers Squibb originator brand Opdyta. Business Standard reported in January 2026 that Opdyta typically cost from around ₹36,000 to over ₹90,000 per vial, depending on the dosage form. That was the price of one vial, not one cycle, and not one course.

The running total was the real problem. Nivolumab is not a single injection. It is a repeated infusion, usually every two or four weeks, continued for as long as the treating oncologist judges it is working and tolerated — often many months. A family looking at that first quote was not looking at one payment. They were looking at the same payment again in a fortnight, and again after that.

The practical consequence was well recognised in Indian oncology long before the biosimilar arrived: courses were interrupted or stopped early for money reasons rather than medical ones. If you started treatment in 2024 or 2025 and stopped for cost, that history is worth telling your oncologist, because the pricing landscape you made that decision in has since changed.

Figures above are indicative published amounts, as of August 2026, sourced from Business Standard reporting of 22 January 2026. They are not a CION price list and not a quote for any patient.

Three things changed in quick succession, and together they reset the economics of this one molecule. A court cleared an Indian biosimilar for sale. That biosimilar launched at roughly a quarter of the reference price. Then the originator patent expired. No other checkpoint inhibitor in India has been through this sequence yet.

This is a factual account of a pricing and regulatory event, not a comment on the merits of any company's product or the ongoing litigation. Availability of a specific brand at a specific hospital is a separate question from what has been approved or launched nationally.

As of August 2026 the published per-vial figures are ₹13,950 (40 mg) and ₹28,950 (100 mg) for the Zydus biosimilar Tishtha, against an indicative ₹36,000 to over ₹90,000 per vial for the originator Opdyta, depending on dosage form. Both sets of numbers come from January 2026 reporting and filings. Neither is a hospital quote, and neither is a CION rate.

What this means in practice is narrower than the headline suggests. A quarter of the price is a real change for families who were rationing cycles, and Zydus has said publicly it expects the launch to widen access. It does not follow that nivolumab is now affordable for everyone, that it is the right medicine for a given cancer, or that a course will be short. The per-vial price is one line in a longer bill, and the sections below break down the rest of it.

A lower price does not widen who nivolumab is suitable for. It is approved for particular cancer types in particular clinical situations, and for a large share of patients it is simply not an option, at any price. That is worth saying plainly on a cost page, because cost pages are where hope tends to outrun eligibility.

Nivolumab is generally not used, or is used only with specialist caution and close discussion of the risks, in people who:

• have a cancer type or stage for which it is not an approved indication, or whose biomarker testing does not support it — this is the largest group by far;
• have an active autoimmune condition, because releasing the brake on the immune system can worsen it;
• are taking high-dose steroids or other immunosuppressive medicines for another condition;
• have had a solid-organ transplant, where checkpoint inhibitors carry a recognised risk of graft rejection;
• have an unresolved serious immune-related reaction from earlier immunotherapy;
• are too unwell overall — a poor performance status — for the monitoring and the possible immune-related side effects that come with this class;
• are pregnant or planning a pregnancy, where the risks require a specific conversation before anything is started.

None of these are absolute rules you can apply to yourself from a web page. They are the reasons an oncologist may say no to nivolumab even when a family can now afford it, and the reason this page cannot tell you whether it applies to your case. Only the treating oncology team, with your scans, pathology and biomarker results in front of them, can answer that.

This page is also not a suitability check for a brand. Choosing between an originator and a biosimilar is a clinical and pharmacy decision made by your treating team, not something to select on price.

Because a vial price is not a cycle price, and a cycle price is not a course price. Those three numbers get used interchangeably in conversation, and that is where most of the confusion about immunotherapy cost begins.

Nivolumab is given by intravenous infusion on a repeating schedule, commonly every two or four weeks. The dose your oncologist writes decides how many vials, and of which strength, the pharmacy has to dispense for a single sitting. Two patients on the same medicine can therefore have very different drug costs per visit.

The rest of the bill sits around the drug:

• Day-care charge — the infusion chair, nursing time and observation period. Immunotherapy at CION centres is given as day care, so this is a same-day charge, not an admission.
• Pre-medication and consumables — lines, fluids, and any medicines given before the infusion.
• Monitoring blood tests — thyroid, liver, kidney and blood-count checks are typically repeated before cycles, because immune-related side effects are picked up on bloodwork before they are felt.
• Review consultation — the oncologist assessment attached to each cycle.
• Response-assessment imaging — periodic scans to see whether treatment is working. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION, and is billed separately from the drug.

Ask any hospital for an itemised quote that separates drug cost, day-care charge and monitoring tests. A single bundled per-cycle number cannot be compared fairly against a published vial price, or against another hospital's bundled number.

A biosimilar is not a generic copy, and it is not a different drug either. It is a biological medicine developed to be highly similar to an already approved reference product, with no clinically meaningful difference in quality, safety or the way it works. The active molecule is nivolumab in both cases.

The distinction matters because biological medicines are grown in living cells rather than made by straightforward chemistry, so an exact molecular copy is not achievable the way it is for a tablet. Regulators handle that with a comparability exercise instead: analytical, non-clinical and clinical data must show similarity to the reference product before approval. CDSCO, India's drug regulator, assessed the Zydus product against those requirements before it reached the market.

What that does not mean is that you should ask for the biosimilar, or refuse it, on your own. Which product is used depends on your protocol, what your hospital pharmacy stocks, whether you are already partway through a course, and your oncologist's judgement. Raise the question, by all means — the cost difference is large enough to be worth asking about — but treat it as a question, not an instruction.

Nivolumab is approved in India for a defined set of cancer indications. Approved indication, biomarker results and prior treatment decide whether the molecule applies to you at all, before brand ever enters the conversation. Guidance from bodies such as NCCN, ESMO and ASCO informs how oncologists in India position checkpoint inhibitors within a treatment plan.

Sometimes, partly, and never assume it from a general page like this one. Coverage depends on the scheme, on whether the hospital is empanelled, and on the exact protocol prescribed — not on the drug's name alone.

Where a government scheme such as Aarogyasri sets a ceiling for a given oncology protocol, that ceiling is fixed by the package, and it does not automatically stretch to cover a full course of a high-cost injectable. Private insurance policies differ on sub-limits for injectable oncology drugs, and cashless approval for immunotherapy protocols can take longer than for standard chemotherapy. A biosimilar's lower price can bring a course closer to a scheme ceiling than the originator did — but whether it actually falls inside one is a question for the hospital's insurance desk, in writing, before treatment starts.

If a relative overseas is funding the treatment, two practical points come up repeatedly. First, ask for the itemised quote described above rather than a lump sum, so the person paying can see what recurs every cycle and what is one-off. Second, get the expected review points in the plan — the dates when scans will reassess whether treatment continues — because those are the moments when the recurring commitment can change, in either direction.

Scheme ceilings and insurance sub-limits change. Any figure quoted to you today should be reconfirmed at the point of admission rather than carried forward from an earlier conversation.

Treat an unusually low price from an unofficial source as a warning sign, not a saving. Counterfeit checkpoint inhibitors have been reported entering the Indian market in the period around patent expiry, and a family under cost pressure is exactly who such an offer is aimed at.

Nivolumab is a biological medicine that must be kept refrigerated within a narrow temperature range from manufacture to infusion. A vial that has been allowed to warm, freeze, or sit outside a documented cold chain may look completely normal and still not be the medicine it is labelled as. There is no way for a patient, a family member, or a hospital nurse to tell by inspection.

• Source the medicine through the treating hospital's licensed pharmacy, or a licensed pharmacy your hospital names, so that batch number, expiry and cold-chain handling are documented.
• Keep the invoice and the batch details. If a side effect is later investigated, or a product recall is issued, those records matter.
• Be wary of vials offered through social media groups, individual resellers, or informal patient networks, however genuine the intention behind the offer.
• If someone offers a price far below the published biosimilar figures above, ask where the vial came from and ask to see the cold-chain documentation before anything is bought.

This is a patient-safety point rather than a commercial one. Now that a legitimate biosimilar exists at roughly a quarter of the reference price, the genuine saving is available through a regulated channel — which removes most of the reason to take a risk outside one.

If you want to see where nivolumab sits among the other medicines in this class, and which of them are cleared for use here, Which Checkpoint Inhibitors Are Approved in India? is the wider map. Cost is only half of what most families need to weigh, and the other half is tolerance — Nivolumab Side Effects covers what to watch for and when a symptom needs urgent attention. For a PD-L1 medicine with a different pricing picture and no Indian biosimilar, see Atezolizumab (Tecentriq): Uses, Cost and Side Effects. And for the full set of molecule guides, comparisons and cost pages in this section, start from Immunotherapy Medicines Explained.